Unable to generate interest, no marketing skills, amateur Management compare to "the real Big Pharma". Two big issues ...CEO and the China deal. If dealing with the Chinese government transferring money should be no issue. So far unable to collect the "5"M ....imagine 50 .......if complete vaccine/booster in the near future but no domestic Big Pharma interest it raises concerns. Try to collect your royalty payments after sharing IP.........
No update on Altucell closing date, no update on current revenue ... uptick in sales???, convenient silent period GNBT/NGIO IPO, it appears no institutional interest etc.
Management/resources the key for still not being listed. If they don't clean up their business plan an IPO will look like a CC .......